Fig. 1: Patient disposition.

A total of 22 patients were treated in the phase 1b dose-escalation cohort (n = 19 with R/R LBCL and n = 3 with R/R FL) and 98 patients in the phase 2 dose-expansion cohort (all with R/R LBCL). PD, progressive disease.
A total of 22 patients were treated in the phase 1b dose-escalation cohort (n = 19 with R/R LBCL and n = 3 with R/R FL) and 98 patients in the phase 2 dose-expansion cohort (all with R/R LBCL). PD, progressive disease.